Skip to main content

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Ceftiofur Sodium

Detailed information about Ceftiofur Sodium

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake
Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus .

What it does:

For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus . Treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica , P. multocida ,...

When it's needed:

For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus .

Commonly reported reactions:

  • (2 reports)
  • (2 reports)
  • (1 reports)

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Talk to a Vet / Find a Vet Near You
Image coming soon
Ceftiofur Sodium

Ceftiofur Sodium

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: MSK

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: MSK
Form: Liquid (Solution), Powder-Sterile
Identifiers:
ANADA: 200421 NADA: 140338 NDC Package: 54771-3362-1 NDC Package: 54771-3362-2 NDC Package: 58597-8170-9 NDC Package: 62157-171-01 NDC Package: 62157-396-01 NDC Product: 54771 NDC Product: 58597 NDC Product: 62157
Source metadata:

Warnings / Contraindications

No contraindication summary is linked yet.

No owner-focused warning rows are linked yet.

Source metadata: No source yet.

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
30
Species represented
2
Most Reported Reactions
Reaction Cases Species Serious cases
2 Cat, Dog 2
2 Cat, Dog 2
1 Dog 1
1 Cat 1
1 Cat 1
1 Dog 1
1 Dog 1
1 Dog 1

Species coverage: Dog (23) Cat (9)

View detailed reaction table
Reaction Species Seriousness Frequency Reports
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Cat Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Cat Non-serious - 1
Dog Serious - 1
Cat Non-serious - 1
Dog Serious - 1
Cat Serious - 1
Cat Serious - 1
Dog Serious - 1
Source metadata:

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 21 • Secondary summaries: 0

Official label facts
Secondary summaries

No source yet.

Source metadata:

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.
Talk to a Vet / Find a Vet Near You
Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Feb 9, 2026, 3:14 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Ceftiofur for Injection Naxcel® Sterile Powder
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: 1 day-old broiler chicks, Beef, Cattle, Dairy, Day old poults, Day-Old Chicks, Dog, Goat, Horse, No Use Class Stated Or Implied, No use class stated or implied, Sheep, Swine, Turkey
Rx/OTC: RX
Form/route: Liquid (Solution), Powder-Sterile • Intramuscular, Subcutaneous
Applications: NADA 140-338 • ANADA 200-421
Documents: 19 (FOI: 15) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 8 • Cat 8 • View
Case summaries: 10 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Top reaction signals
Abdominal pain (1) Abnormal pupil light reflex (1) ABNORMAL TEST RESULT, THYROID NOS (1) Adrenal gland disorder NOS (1) Anaemia NOS (1) Anaemia NOS (1) Anaphylaxis (1) Anorexia (1) Anxiety (1) Ataxia (1) Behavioural disorder NOS (1) Bloated stomach (1) Bruising (1) Cardiac enlargement (1) Cholecystitis (1) Circulatory shock (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200421 NADA: 140338 NDC Package: 54771-3362-1 NDC Package: 54771-3362-2 NDC Package: 58597-8170-9 NDC Package: 62157-171-01 NDC Package: 62157-396-01 NDC Product: 54771 NDC Product: 58597 NDC Product: 62157
Package NDC Product NDC Form / Route Status
54771-3362-1 54771 -
54771-3362-2 54771 -
58597-8170-9 58597 -
62157-171-01 62157 -
62157-396-01 62157 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • UCM478009.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • UCM490826.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • N140338_Supp_03-15-1991.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • N140338_Supp_08_04_1992.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • UCM539438.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • N140338_Supp_08-24-1995.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • UCM470933.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • N140338_Supp_10_25_96.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • ucm049841.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • ucm049842.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • ucm049843.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • ucm049844.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • ucm049846.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • ucm049847.pdf • FOI summary • Official • Sept. 6, 2022
    FDA FOI summary for application 140338
  • UCM307677.pdf • FOI summary • Official • Jan. 16, 2018
    FDA FOI summary for application 200421

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 17 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Leucocytosis NOS, Anaemia NOS, Elev… (Official, 2026-02-12)
  • usage: For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus . Treatment of bovine respiratory disease (shipping fever, pneumo… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Naxcel® Sterile Powder
RX
Ceftiofur Sodium
Liquid (Solution) • Intramuscular, Subcutaneous
Label highlights
Official documents
Zoetis Inc. NADA 140-338 Approved Sep 6, 2022
Ceftiofur for Injection
RX
Ceftiofur Sodium
Powder-Sterile • Subcutaneous, Intramuscular
Label highlights
Official documents
Hospira, Inc. ANADA 200-421 W Jan 16, 2018

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied • Horse, Not For Meat Production • Goat, No Use Class Stated Or Implied • No use class stated or implied • Beef • Dairy • Day old poults • 1 day-old broiler chicks • Sheep, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of aqueous solution constituted from ceftiofur sodium powder contains 50 milligrams (mg) ceftiofur equivalents.
Horses
Indication
For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus.
Dosage
2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body weight by intramuscular injection. Treatment should be repeated every 24 hours, continued for 48 hours after clinical signs have disappeared, and should not exceed 10 days. A maximum of 10 mL should be administered per injection site.
Limitations
Cattle
Indication
Treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, P. multocida, and Histophilus somni in beef and dairy cattle
Dosage
0.5 to 1.0 mg/lb body weight by intramuscular or subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.
Limitations
Indication

For treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.

Dosage
0.5 to 1.0 mg/lb body weight by intramuscular or subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.
Limitations
Swine
Indication
For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
Dosage
3 to 5 mg per kilogram (/kg) body weight by intramuscular injection for 3 consecutive days.
Limitations
Sheep
Indication
For treatment of sheep respiratory disease (pneumonia) associated with M. haemolytica and P. multocida.
Dosage
0.5 to 1.0 mg/lb body weight by intramuscular injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.
Limitations
Chickens (Day Old Chicks)
Indication
For control of early mortality associated with Escherichia coli organisms susceptible to ceftiofur in day-old chicks.
Dosage
0.08 to 0.20 mg as a single subcutaneous injection in the neck.
Limitations
Turkeys (Day Old Poults)
Indication
For control of early mortality associated with E. coli organisms susceptible to ceftiofur in day-old poults.
Dosage
0.17 to 0.5 mg as a single subcutaneous injection in the neck.
Limitations
Dogs
Indication
Treatment of canine urinary tract infections associated with E. coli and Proteus mirabilis.
Dosage
1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection. Treatment should be repeated at 24-hour intervals, continued for 48 hours after clinical signs have disappeared, for 5 to 14 days.
Limitations
Goats
Indication
For treatment of caprine respiratory disease (goat pneumonia) associated with M. haemolytica and P. multocida.
Dosage
0.5 to 1.0 mg/lb body weight by intramuscular injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.
Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Goat, No Use Class Stated Or Implied • Swine, No Use Class Stated Or Implied • Cattle, No Use Class Stated Or Implied • No Use Class Stated Or Implied • Turkey, Poults, Day Old • Day-Old Chicks • Sheep, No Use Class Stated Or Implied
<strong>Cattle</strong>
Indication
For treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.  Also, for treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
Dosage
0.5 to 1.0 mg per pound (1.1 to 2.2 mg/kg) of body weight (1-2 mL reconstituted sterile solution per 100 lbs body weight). Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days. Additional treatments may be given on days four and five for animals which do not show a satisfactory response (not recovered) after the initial three treatments
Limitations
<strong>Swine</strong>
Indication
For treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
Dosage
1.36 to 2.27 mg per pound (3.0 to 5.0 mg/kg) of body weight (1 mL of reconstituted sterile solution per 22 to 37 lbs body weight). Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days.
Limitations
<strong>Sheep</strong>
Indication
For treatment of sheep respiratory disease (sheep pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.
Dosage
0.5 to 1.0 mg per pound (1.1 to 2.2 mL reconstituted sterile solution per 100 lbs body weight).  Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days. Additional treatments may be given on days four and five for animals which do not show a satisfactory response (not recovered) after the initial three treatments.
Limitations
<strong>Goats</strong>
Indication
For treatment of caprine respiratory disease (goat pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.
Dosage
0.5 to 1.0 mg per pound (1.1 to 2.2 mg/kg) of body weight (1-2 mL reconstituted sterile solution per 100 lbs body weight). Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days. Additional treatments may be given on days four and five for animals which do not show a satisfactory response (not recovered) after the initial three treatments.
Limitations
<strong>Horses</strong>
Indication
For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus.
Dosage
1.0 to 2.0 mg per pound (2.2 to 4.4 mg/kg) of body weight (2-4 mL reconstituted sterile solution per 100 lb body weight). A maximum of 10 mL may be administered per injection site.  Treatment should be repeated at 24-hour intervals, continued for 48 hours after clinical signs have disappeared and should not exceed 10 days.
Limitations
<strong>Dogs</strong>
Indication
For the treatment of canine urinary tract infections associated with Escherichia coli and Proteus mirabilis.
Dosage
1.0 mg per pound 2.2 mg/kg) of body weight (0.1 mL reconstituted sterile solution per 5 lbs body weight). Treatment should be repeated at 24 hour intervals for 5-14 days.
Limitations
<strong>Day-Old Chicks</strong>
Indication
For the control of early mortality, associated with E. coli organisms susceptible to ceftiofur, in day-old chicks.
Dosage
0.08 to 0.20 mg/chick. One mL of the 50 mg/mL reconstituted solution will treat approximately 250 to 625 day-old chicks.
Limitations
<strong>Day-Old Turkey Poults</strong>
Indication
For the control of early mortality, associated with E. coli organisms susceptible to ceftiofur, in day-old turkey poults.
Dosage
0.17 to 0.5 mg/poult. 1 ml of the 50 mg/mL reconstituted solution will treat approximately 100 to 294 day-old turkey poults.
Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary
    To establish a 4-day pre-slaughter withdrawal period for cattle
  • Summary
    For the treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis type 2.
  • Summary
    This supplement updates survey microbiological data and adds the National Committee for Clinical Laboratory Standards’ (NCCLS) interpretive criteria for equine isolates to the NAXCEL Sterile Powder package insert.
  • Summary
    This supplement provides four specific changes to the product insert, 1) revision of the “clinical microbiology” section to update the MIC table using the new MIC data for ceftiofur, 2) the addition of a table listing acceptable quality control ranges for ceftiofur, 3) the addition of the latest National Committee for Clinical Laboratory Standards (NCCLS) reference at the end of the insert, and 4) clarification of the statement under “Storage Conditions” dealing with the storage of reconstituted Naxcel via freezing.
  • Summary
    Provides for the use of a subcutaneous (SC) route of administration for NAXCEL® Sterile Powder in cattle.
  • Summary
    The approval of this supplement will allow for the use of ceftiofur sodium (NAXCEL? Sterile Powder) for the treatment of bacterial pneumonia in goats to be added to the previously approved NAXCEL label.
  • Summary

    The approval of this supplement will allow for the use of ceftiofur sodium (NAXCEL Sterile Powder) for the treatment of bacterial pneumonia in sheep.

  • Summary
    Provides for an additional species, day-old turkey poults, to be added to the previously approved product, NAXCEL® Sterile Powder; also provides for revision of the chick indication.
  • Summary

    Provides for the use of ceftiofur sodium (NAXCEL® Sterile Powder) in cattle for a new indication.

  • Summary
    The supplement provides data in support of a request for approval of Naxcel ® Sterile Powder for an additional species (equine). The issue of the Freedom of Information (FOI) Summary should be considered an extension of previously approved version describing data in support of Naxcelreg., NADA 140-338, approved as a treatment for respiratory disease in cattle January 25, 1988.
  • Summary

    This supplement provides for an additional species, swine, to be added to the previously approved product, NAXCEL®.

  • Summary

    Provides for the use of ceftiofur sodium (NAXCEL Sterile Powder) in lactating dairy cattle, a new class of animal, for the same indications approved in the parent NADA.

  • Summary
    This supplemental application provides for a change in the approved dosage of 0.5 mg/lb body weight to a range of 0.5 mg to 1.0 mg ceftiofur sodium/lb of body weight.
  • Summary
    Naxcel Sterile Powder is indicated for treatment of bovine respiratory disease (shipping fever, pneumonia).
  • EA 140-338
  • FONSI 140-338
  • EA 140-338
  • FONSI 140-338
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    Cattle: For treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. Also, for treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus. 
    Swine:     For treatment/control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Actinobacillus (Haemophilus) pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, and Streptococcus suis.
    Sheep:     For treatment of sheep respiratory disease (sheep pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.
    Goats:     For treatment of caprine respiratory disease (goat pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.
    Horses:     For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus.
    Dogs:     For the treatment of canine urinary tract infections associated with Escherichia coli and Proteus mirabilis.
    Day-Old Chicks:     For the control of early mortality, associated with E. coli organisms susceptible to ceftiofur, in day-old chicks.
    Day-Old Turkey Poults: For the control of early mortality, associated with E. coli organisms susceptible to ceftiofur, in day-old turkey poults.orum and Bacteroides melaninogenicus.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus . Treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica , P. multocida , and Histophilus somni in beef and dairy cattle For treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus .

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

No approved contraindication text is linked yet. Review FDA label highlights and openFDA safety reports before making treatment decisions.

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 8 and Cat 8 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog
Digestive
Vomiting (8) Loss of appetite (3)
Neurologic
Tiredness (lethargy) (6)
Other
Death (5) Leucocytosis NOS (5) Anaemia NOS (4) Elevated amylase (4) Abdominal pain (3)
Cat
Digestive
Loss of appetite (1)
Neurologic
Unsteady walking (ataxia) (1)
Other
Fever (3) Death by euthanasia (2) Dehydration (2) Not drinking (2) Trouble breathing (dyspnea) (2) Anaemia NOS (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Affenpinscher, Male, 9 year, 7.5 kilogram • Drug: MSK, Unknown • Reactions: Loss of appetite, Constipation, Liver disorder NOS, Elevated serum alkaline phosphatase, Elevated gamma-glutamyl transferase… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-009374
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 9.00 Year
  • Weight: 7.500 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Loss of appetite Constipation Liver disorder NOS Elevated serum alkaline phosphatase Elevated gamma-glutamyl transferase Elevated total bilirubin Elevated amylase Tiredness (lethargy) Laboured breathing Overdose Labelled drug-drug interaction medication error Cardiac enlargement Heart murmur Gall bladder & bile duct disorder NOS Jaundice Panting Foaming at the mouth Not eating Bloated stomach Vomiting Vomiting foam
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 4 year, 5.271 kilogram • Drug: MSK, Powder, Subcutaneous, Dose: 0.30 mL per animal • Reactions: Dehydration, Death by euthanasia, Fever, Not eating, Not drinking… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-006900
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 5.271 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Powder
  • Dose: 0.30 mL per animal
Reactions Reported:
Dehydration Death by euthanasia Fever Not eating Not drinking Elevated creatinine Lymphopenia Neutropenia Leucopenia NOS Hypoalbuminaemia Low platelet count Elevated total bilirubin Anaemia NOS Reduced globulins Elevated alanine aminotransferase
Outcomes: Euthanized

Dog, ['Chinese Crested Dog (unspecified)', 'Dog (unknown)'], Male, 4 year, 9.11 kilogram • Drug: MSK, Unknown • Reactions: Vomiting, Lateral recumbency, Dull reflexes, Tachypnoea, Liver failure… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2024-US-078217
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 4.00 Year
  • Weight: 9.110 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Vomiting Lateral recumbency Dull reflexes Tachypnoea Liver failure Dilated pupils Tachycardia Collapse NOS Urinary incontinence Coagulopathy Faecal incontinence Profuse bleeding Unresponsive to stimuli Abnormal pupil light reflex Circulatory shock Strabismus Leucocytosis NOS Pale mucous membrane Elevated liver enzymes NOS Not eating Anaphylaxis Fixed pupil
Outcomes: Recovered/Normal

Dog, Shepherd Dog - German, Male, 1 year, 27.6 kilogram • Drug: MSK, Powder, Unknown • Reactions: Lack of efficacy (virus) - parvovirus, Paraphimosis • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2024-US-079903
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 1.00 Year
  • Weight: 27.600 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Powder
Reactions Reported:
Lack of efficacy (virus) - parvovirus Paraphimosis
Outcomes: Recovered/Normal

Dog, Shepherd Dog - German, Male, 1 year, 27.6 kilogram • Drug: MSK, Unknown • Reactions: Lack of efficacy (virus) - parvovirus, Paraphimosis • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2024-US-067873
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 1.00 Year
  • Weight: 27.600 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Lack of efficacy (virus) - parvovirus Paraphimosis
Outcomes: Outcome Unknown

Dog, ['Crossbred Canine/dog', 'Maltese'], Female, 8 year, 8.165 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 20 Milligram per dose, Frequency: 1 per day • Reactions: Lack of efficacy - NOS, Anaemia NOS, Death by euthanasia, Elevated amylase, Hypophosphataemia… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2024-US-062683
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 8.165 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 20 Milligram per dose
  • Frequency: 1 per day
Reactions Reported:
Lack of efficacy - NOS Anaemia NOS Death by euthanasia Elevated amylase Hypophosphataemia Hypokalaemia Monocytopenia Behavioral disorder (unspecified) Tachypnoea Hyperthermia Elevated lipase Hypochloraemia Hyponatremia Eosinopenia Decreased percentage of reticulocytes Hepatomegaly Gall bladder & bile duct disorder NOS Cholecystitis Thrombocytopenia Abdominal pain Nasal discharge Hepatopathy Liver nodules Adrenal gland disorder NOS Heart murmur Bruising Hypertension Tachycardia Weight loss ABNORMAL TEST RESULT, THYROID NOS Diabetic ketoacidosis Anxiety Steatitis
Outcomes: Euthanized

Cat, Domestic Shorthair, Female, 8 year • Drug: MSK, Powder, Unknown, Dose: 20 Milligram per unknown • Reactions: Seizure NOS, Drug administration error • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2021-US-027414
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 8.00 Year
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Powder
  • Dose: 20 Milligram per unknown
Reactions Reported:
Seizure NOS Drug administration error
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 5 year, 4.536 kilogram • Drug: MSK, Powder, Subcutaneous • Reactions: Fever, Injection site lesion, Injection site necrosis, Decreased appetite, Not drinking… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2018-US-042162
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 5.00 Year
  • Weight: 4.536 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Powder
Reactions Reported:
Fever Injection site lesion Injection site necrosis Decreased appetite Not drinking Skin slough
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.